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Background: Paclitaxel induced fatigue still remains underrecognized and undertreated, partly because of limited
understanding of its pathophysiology and lack of effective treatments. This study is aim to evaluate the anti-fatigue
effects and mechanism of Bu-Zhong-Yi-Qi pill in murine 4 T1 breast cancer mice were treated with paclitaxel.
Methods: Breast cancer mice established with murine 4 T1 cells were randomly and repectively divided into five
groups: negative control group (NC), tumor control group (TC), paclitaxel group (PTX), Bu-Zhong-Yi-Qi pill group
(BZYQ) and Bu-Zhong-Yi-Qi pill plus paclitaxel group (BZYQ + PTX). The mice were administered for 21 days. During
this period, the tumor volume, body weight and the weight-loaded swimming time were measured. After the last
administration, all mice were sacrificed, weighted the tumor, measured immune cell cytokines and oxidative stress
indicator. The remaining 10 mice in each group were observed for survival analysis.
Results: Treatments with BZYQ + PTX and PTX significantly reduced the rates of tumor volume in comparison with
TC starting on the 9th day and the 18th day respectively (P < 0.05-0.01), and presented decreased tumor weight
compared to TC (P < 0.05-0.01). Compared with mice in TC group, the median survival time and the average
survival time in BZYQ + PTX group, BZYQ group and PTX group were significantly prolonged (P < 0.05-0.01). The
swimming time of the BZYQ + PTX group gradually increased, which is longer than the PTX group on Day 14
and Day 21 (P < 0.01). The level of TNF-α was lower in BZYQ + PTX group than PTX group (P < 0.01). The level of
SOD activity in BZYQ + PTX group was lower than the NC group (P <0.01), but much higher than the PTX group
(P < 0.01). The level of MDA of BZYQ + PTX group was higher than the NC group (P < 0.01), but significant lower
than the PTX group (P < 0.01).
Conclusions: BZYQ has the potential of alleviating paclitaxel chemotherapy-related fatigue in 4 T1 breast cancer
mice by reducing the serum levels of TNF-α and modulating the level of MDA and the SOD activity.Background
Breast cancer is the most common cancer affecting
women at all ages globally. With the development of de-
tection and treatment, the number of women who sur-
vive from breast cancer has increased significantly in
recent years. Five-year survival rates for localized breast* Correspondence: zhaoxs0609@163.com
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reproduction in any medium, provided the orcancer have climbed to 98%, resulting in an estimated
2.6 million North American women living in the after-
math of breast cancer [1]. As survival times increase, ad-
dressing the impact of breast cancer and its treatment
on long-term outcomes have become increasingly im-
portant [2]. Fatigue is the most frequently reported side
effect of any chemotherapy, including paclitaxel. It is re-
ported that as many as 68% of breast cancer patients
have fatigue during paclitaxel chemotherapy, and fatigue
is a key reason for patient discontinuation of treatment
[3]. After completion of treatment, as many as 70% of
breast cancer patients report continued fatigue, which
has been documented to persist for up to 10 years [4,5].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cal approaches have been studied, paclitaxel induced fa-
tigue still remains underrecognized and undertreated,
partly because of limited understanding of its patho-
physiology and lack of effective treatments [6,7]. There-
fore, the development with more effective treatments
would be instrumental in the ability to fight paclitaxel
induced fatigue.
Chinese herbal formulae Bu-Zhong-Yi-Qi Decoction
(“Bojungikki-tang” in South Korea or “Hochu-ekki-to” in
Japanese) is composed of 10 species of medicinal plants
(as shown in Table 1) [8], has been widely used in trad-
itional medicine in China, Japan, Korea and so on. This
herbal prescription has been identified as an effective
medication to improve the quality of life and nutritional
status [9]. Bu-Zhong-Yi-Qi Decoction is useful not only
for the improvement of daily activity of chronic fatigue
syndrome [10,11], but also for the enhancement of anti-
tumor effect [12-16]. Some clinical studies of Bu-Zhong-
Yi-Qi Decoction have shown beneficial effects on
cancer-related fatigue and quality of lives among cancer
patients [17].
Based on the anti-fatigue and antitumor effects, we sup-
posed that Bu-Zhong-Yi-Qi pill could be an alternative
therapy to chemotherapy-related fatigue, and as far as we
know, there has not been studied for its effect on chemo-
therapy–related fatigue. In this study, we have focused on
the weight-loaded swimming capability, the tumor growth,
and the biochemical markers level of Bu-Zhong-Yi-Qi pill
in 4 T1 murine breast cancer model treated with paclitaxel
to evaluate whether Bu-Zhong-Yi-Qi pill has beneficial ef-
fects on chemotherapy–related fatigue.
Methods
Reagents
Paclitaxel (PTX) was purchased from Medisan Pharma-
ceutical Co., Ltd. (Harbin, China). Bu-Zhong-Yi-Qi pill
(BZYQ) was acquired from Wanxi Pharmaceutical Co.,





Radix Angelicae Sinensis 8.3%
Radix Codonopsis 8.3%
Rhizoma Atractylodis Macrocephalae 8.3%
Rhizoma Cimicifugae 8.3%
Pericarpium Citri Reticulatae 8.3%
Rhizoma Zingiberis Recens 2.8%
Fructus Jujubae 5.6%and their proportions were shown in Table 1. The fetal
calf serum and RPMI-1640 medium were purchased
from Jinuo Biological Pharmaceutical Co., Ltd. (Hangzhou,
China). Reagent kits for the determination of TNF-α, IL-6
and IL-1β were purchased from Huamei Biotechnology
Co. (Wuhan, China). Assay kits for the determination of
SOD and MDA were acquired Beyotime Institute of Bio-
technology (Haimen, China).
4 T1 cell culture
4 T1 murine mammary carcinoma cells which were ac-
quired from Shanghai Institute of Biochemistry and Cell
Biology of Chinese Academy of Sciences (Shanghai,
China) were grown in tissue culture flasks at 37°C in
humidified atmosphere of 5% CO2 and were maintained
as monolayer cultures in RPMI 1640 containing 10%
heat-inactivated fetal calf serum (FCS) and antibiotics
(100 units/ml penicillin and 100 g/ml streptomycin).
Animals
Female BALB/c mice (7 weeks old, 16 ~ 20 g) were ob-
tained from Medical Laboratory Animal Center of
Guangdong province (Approval No. SCXK (Yue) 2008–
0002, Foshan, China). The mice were acclimatized for
1 week before use and housed at a room temperature
of 23°C ± 1°C with a 12 h-light and 12 h-dark cycle
(lights on from 6: 00 am to 6: 00 pm). Food and water
were available ad libitum. Mice were treated in compli-
ance with the current law and the Guiding Principles for
the Care and Use of Laboratory Animals approved
by Southern Medical University Animal Care and Use
Committee (Approval No.2013058).
Experimental design
Mice were taken weight-loaded swimming test before
the experiment, and the mice which swam for long or
short period were screened out. Then 30 mice were ran-
domly chosen as the normal control group (NC). The
rest mice were used for establishing tumor grafts model.Major chemical constituents
Astragalus Polysaccharides, Astragaloside I-VIII,
Glycyrrhizic acid, glycyrrhetinic acid, Liquiritin
Saikosaponin a, Saikosaponin d, Saikosaponin c, Saikochrome A
Z-ligustilide, Ferulic Acid, Angelica Polysaccharides
Lobetyolin, Lobetyolinin, tanshenoside I, Geniposide, syringin
Butenolide I, Butenolide II, Biatractylolide, Atractylone
27-Deoxyactein, Cimicifugic acids A-E, Ferulic acid, Isoferulic acid
Hesperidin, Nobiletin, D-Limonene, β-myrcene
Gingerol, Diarylheptanoids, α-pinene, β-phellandrene, Ginger flavonoids
Zizyphus saponln)I-III, Jujuboside A, Jujuboside B, stepharine
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fourth mammary fat pad of BALB/c mice [18]. 120 mice
whose tumor had a mean volume of 50 ~ 100 mm3 were
chosen on Day 7, and were randomly divided into four
groups, in each group, 30 mice randomly divided into
three subgroups. The four groups that were named as
the PTX group (PTX, i.p., every two days, 10 mg/kg,
10 ml/kg [18] and normal saline, p.o., once daily, 20 ml/
kg) (PTX), the BZYQ group (BZYQ, p.o., once daily,
1.5 g/kg, 20 ml/kg, 10x patient’s clinical dosage (same as
clinical equivalent dose) and normal saline, i.p., every
two days, 10 ml/kg.) (BZYQ), the BZYQ (p.o., once daily,
1.5 g/kg, 20 ml/kg) plus PTX (i.p., every two days,
10 mg/kg, 10 ml/kg) group (BZYQ + PTX) and the
tumor control group (TC). The TC and the NC groups
received normal saline in volumes equivalent to those
used for injection and intragastric administration of the
drugs. The duration of treatment lasts 21 days. Tumors
sizes of subgroup 1 of each group were measured every
three days using calipers and tumor volume was calculated
with the use of the following formula: tumor volume
(mm3) = L ×W2 × 0.52, where L is the longest diameter, W
is the perpendicular short diameter. And body weight was
weighed every 7 days. At the end of the experiments, mice
were fasted for 8 hours, and then the mice were anesthe-
tized with pentobarbital sodium and sacrificed. Tumors
were excised from the mice and weighed. The subgroup 2
were taken out from each group for weight-loaded swim-
ming test, and the subgroup 3 in each group were ob-
served for survival analysis.
Weight-loaded swimming test
The subgroup 2 were taken out from each group for
weight-loaded swimming test every 7 days. The proced-
ure used in this experiment was similar to that described
by Porsolt RD, et al. [19]. Briefly, 60 min after the last
therapy, the mice were placed individually in a swim-
ming pool (30 cm high, 25 cm in diameter) in which the
mice could only support themselves by touching the bot-
tom with their feet (at 25°C ± 1°C). A tin wire (7% of
body weight) was loaded on the tail root of each mouse.
The swimming period was regarded as the time spent by
the mouse floating in the water with struggling and mak-
ing necessary movements until exhausting its strength.
The mice were assessed to be exhausted when they
failed to rise to the surface of water to breathe within a
10 s period. At the end of the session, the mice were
taken out from the water, dried with a paper towel, and
placed back in their home cages. Water in the container
was drained after each session.
Determination of serum IL-1β, TNF-α and IL-6
At the end of the experiments, mice were fasted for
8 hours, and then the mice were anesthetized withpentobarbital sodium and sacrificed. The blood samples
of the mice were collected in tubes without anticoagu-
lant by removing the left eyeball. Serum was prepared by
centrifugation at 1000 × g, 4°C for 15 min. The blood
serum was tested to determine the concentration of
IL-1β, TNF-α and IL-6. The concentration of IL-1β,
TNF-α and IL-6 were tested using the following the rec-
ommended procedures which were provided by the kits.
Determination of muscle superoxide dismutase(SOD)
activity and malondialdehyde (MDA)
After the blood was collected, the gastrocnemius muscle
of the mice was immediately dissected, homogenized
with 20 mm Hepes buffer and centrifuged at 1400 × g,
4°C for 5 min. The resulting supernatant was removed
and stored at −80°C for the following analysis. The levels
of SOD activities and MDA were measured with a kit
following the manufacturer’s protocol.
Statistical analysis
All data were expressed as the mean ± standard devi-
ation (SD) in the tables and indicated by vertical bars in
the figures. Differences between groups were determined
by ANOVA and Student’s t-test. For the survival time of
animals, Kaplan-Meier curves were established for each
group, and the survivals were compared by the log-rank
test. Probability value P less than 0.05 was considered
significant.
Result
Effects of body weight
Changes in mice body weights were recorded both be-
fore and after the treatment. The results are shown in
Figure 1. The body weight was measured at the begin-
ning of the experiment (week 0) and 3 weeks after treat-
ment regular intervals. It was found that the body
weight of the NC and BZYQ groups was obviously in-
creasing compared with the baseline in week 1(P < 0.05)
and the other three groups did not show any obvious
changes (P > 0.05). The weight showed lower for TC,
BZYQ + PTX and PTX groups than the NC group after
2 weeks (P < 0.01), and the body weight of the other four
groups were all declining compared with the NC group
after 3 weeks(P < 0.01), but there were no great differ-
ence among the four groups.
Effects on tumor’s weight and volume
We examined the antitumor activity of BZYQ on an im-
plant model of 4 T1 breast cancer separately and in
combination with PTX, measured tumor volume at
regular intervals and weighted the tumor after the mice
were sacrificed after treatment lasts 21 days. As shown
in Figures 2 and 3, treatments with BZYQ + PTX and
PTX significantly reduced the rates of tumor volume in
Figure 1 Effects on body weight of mice. Compared with the baseline. * P < 0.05, **P < 0.01. Compared with the NC, ##P < 0.01. n = 10.
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18 respectively (P < 0.05), and presented decreased
tumor weight compared to TC (BZYQ + PTX, P < 0.01.
PTX, P < 0.05), but the difference between the two
groups was not significant (P > 0.05). Compared to TC,
the rates of tumor growth did not reduce obviously in
BZYQ with separate treatment (P > 0.05).
Effects on the survival time of tumor-bearing mice
As shown in Figure 4. Compared with mice in TC
group, the median survival time and the average survival
time in BZYQ + PTX group, BZYQ group and PTX
group were significantly prolonged (P < 0.05-0.01). Com-
pared with mice in PTX group, the median survival time
and the average survival time in BZYQ + PTX group
were not significantly prolonged (P > 0.05).
Effects on the weight-loaded swimming test
The anti-fatigue activity of the BZYQ was measured as
the swimming endurance capacity of 4 T1 breast cancerFigure 2 Tumor’s volume. Compared with TC, *P < 0.05, **P < 0.01. n =mice. Change of swimming time during the experimental
period was shown in Figure 5. The swimming time of
all groups had no significant difference before the inter-
vention (P > 0.05). The NC group presented gradually in-
creasing swimming time, while the TC group showed a
declining swimming time, the swimming time of the PTX
group and the BZYQ+ PTX group were significantly de-
creasing after the treatment compared with the NC, TC
and BZYQ groups (P < 0.05 ~ 0.01) in week 1. The swim-
ming time of the BZYQ+ PTX group gradually increased
and was longer than the PTX group in week 2 and week 3
(P < 0.01), consistent with the TC and BZYQ group.
Effects on serum TNF-α, IL-6 and IL-1β
As shown in Table 2, mice bearing breast cancer tumors
exhibited higher levels of TNF-α, IL-6 and IL-1β of
than the NC group (P < 0.05-0.01). The BZYQ + PTX
group showed a lower level of TNF-α than the PTX group
(P < 0.01), but the levels of IL-6 and IL-1β between the
two groups had no significant difference (P >0.05).10.
Figure 3 Tumor’s weight. Compared with TC, * P<0.05, **P<0.01. n= 10.
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To gain better insight into the underlying mechanisms of
BZYQ’s effect, we detected changes of SOD activity and
MDA content in mice muscle. As shown in Table 3, the
PTX group showed a decreased SOD activity compared
with the other four groups (P < 0.01), the level of SOD
activity of BZYQ+ PTX group was lower than the NC
group (P <0.01), but much higher than the PTX group
(P < 0.01). The PTX group showed an increased MDA
level compared with the other four groups (P < 0.01), the
level of MDA of BZYQ+ PTX group was higher than theFigure 4 Effect on the survival time of tumor-bearing mice. ComparedNC group (P < 0.01), but much lower than the PTX group
(P <0.01).
Discussion
Fatigue is one of the most common side effects of pacli-
taxel chemotherapy which not only compromises patients’
quality of life, but also diminishes physical activity, result-
ing in limited treatment and increased morbidity. However,
there were very few pharmacological drugs or therapies
available for the treatment of chemotherapy-related fatigue.
In this study, we used BALB/c mice that were treated with
PTX in a tumor-bearing state to mimic a chemotherapy-
related fatigue situation, the weight-loaded swimming time
of the mice was used for the evaluation of fatigue related
to chemotherapy. And we used the model to evaluate the
effect of Bu-Zhong-Yi-Qi pill on the fatigue caused by pac-
litaxel. In our model, the weight-loaded swimming time
was significantly reduced in response to administration of
PTX starting in the first week after treatment and persist-
ing for as long as 3 weeks consistent with the prior studies
[20]. The swimming time of the BZYQ+ PTX group grad-
ually increased from week 2 and longer than the PTX
group, consistent with the TC and BZYQ group. It is indi-
cated that BZYQ enhanced the swimming capacity of PTX
treated tumor-bearing mice confirming the anti-fatigue
property of BZYQ.
It has been speculated that the fatigue that occurs in can-
cer patients during treatment with paclitaxel chemotherapywith TC, **P < 0.01. n = 10.
Figure 5 Weight-loaded swimming time of all the groups.
Compared with the TC, *P < 0.05, **P < 0.01. Compared with the NC, #P
< 0.05, ##P < 0.01. Compared with the PTX, ΔP < 0.05, ΔΔP < 0.01. n = 10.
Table 3 Muscle levels of MDA and SOD activity in mice
(n = 10)
Groups MDA (nmol/mgPr) SOD (U/mgPr)
NC 5.16 ± 0.80 55.08 ± 4.33
TC 6.18 ± 0.73##** 50.46 ± 3.16#**
PTX 8.30 ± 1.30## 33.91 ± 3.12##
BZYQ 6.33 ± 0.65##** 50. 43 ± 2. 30##**
BZYQ + PTX 6.99 ± 0.81##* 47.26 ± 3. 80##**
Compared with the NC, #P < 0.05, ##P < 0.01.
Compared with the PTX, *P < 0.05,**P < 0.01.
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tory cytokines, and several studies have reported that pacli-
taxel is capable of inducing the expression of TNF-α, IL-1β,
IL-6, IL-8, ICAM-1, NO synthetase, metaloproteinases and
MCP-1 and causes the phosphorylation of MAP kinases
[21]. Paclitaxel up-regulates IL-8 and IL-6 expression in
human lung [22] and ovarian carcinoma cell lines [23]. It
increases expression of IL-1β in human monocytes and in
breast cancer cell lines, MCF-7 and ZR-75-1 [24]. It also
has endotoxin-like effects on human macrophages inducing
the release of IL-1β and TNF-α [25]. In these cytokines, the
TNF-α, IL-1β and IL-6 play important roles in the develop-
ment of fatigue [26-29]. Reports demonstrated that the
Bu-Zhong-Yi-Qi pill could improve systemic inflammation
and nutritional status by reducing the production of TNF-α
and IL-6 [30-33]. In the study, we observed that PTX
induced increased levels of TNF-α, IL-1β and IL-6, and
the BZYQ could reduce the serum level of TNF-α but
cannot decrease the levels of IL-1β and IL-6 up-
regulated by PTX. These observations suggest that the
level of TNF-α may be correlated with the anti-fatigue
effect of BZYQ because of the possibility that elevated
TNF-α level can lead to increased oxidants and muscle
weakness in skeletal muscle according to mediate the
majority of signaling through TNFR1 [34-36].
Growing evidence indicates that exposure of elevated
oxidants is known to cause muscle weakness and accel-
erate the development of fatigue [37-39]. Except for
being produced by tumors themselves [40], the oxidativeTable 2 Serum levels of TNF-α, IL-6 and IL-1β in mice (n = 10)
Groups TNF-α (pg/mL) IL-6 (pg/mL) IL-lβ (pg/mL)
NC 120.22 ± 6.41 21.77 ± 1.01 108.03 ± 6.24
TC 127.32 ± 5.54#** 23.27 ± 1.60#** 114.94 ± 7.05#*
PTX 142.30 ± 8.79## 25.43 ± 1.49## 122.21 ± 7.45##
BZYQ 129.92 ± 9.42#** 24.07 ± 1.24##* 115.55 ± 5.94#*
BZYQ + PTX 132.33 ± 11.09##* 26.62 ± 2.45## 121.26 ± 11.04##
Compared with the NC, #P < 0.05,##P < 0.01.
Compared with the PTX, *P < 0.05,**P < 0.01.stress state is always directly or indirectly produced
by numerous chemotherapeutic agents. Some chemo-
therapeutic agents that include a quinone moiety in their
chemical structure can directly produce a state of oxida-
tive stress by interacting with molecular oxygen and
undergoing redox cycling, leading to the generation of
reactive oxygen species (ROS) [41]. Other chemothera-
peutic agents can indirectly produce a state of oxidative
stress by decreasing antioxidant levels, crippling the
cell’s defenses against elevated oxidants [42]. In the
present study, we found that the PTX group demon-
strated a significantly decreasing muscle SOD activity
and higher MDA level compared with the NC and TC
groups, while the BZYQ + PTX group up-regulated the
SOD activity and decreased the levels of MDA to that of
the PTX group. On the other hand, the TC and BZYQ
groups also demonstrated a significantly decreasing
muscle SOD activity and higher MDA level compared
with the NC group, but there was no significant differ-
ence between the two groups. Lipid peroxidation, which
is a normal phenomenon that occurs continuously at
low level is the most common consequence of oxidative
stress. MDA is the last product of lipid peroxidation and
is toxic to cells and cell membranes [43]. The natural
cellular antioxidant enzymes SOD is accepted one of the
most important physiological antioxidants against free
radicals which prevent subsequent lipid peroxidation
by speeding their dismutation [44]. As shown in a prior
study that BZYQ can partly protect the gastric mucosa
from ethanol-induced acute gastric injury by increasing
the antioxidant status [45]. Radix Astragali, Radix Bupleuri
and Glycyrrhizae, the major components of BZYQ, have
been reported their anti-oxidative properties. Astragalo-
side IV (AS-IV), the active component of Radix Astragali,
acted as an antioxidant inhibiting ROS generation and the
reducing LPO content in culture-activated HSCs [46]. Sai-
kosaponins are isolated as active ingredients of Radix
Bupleuri, showed potent anti-inflammatory activities [47],
anti-ulcerative [48], platelet activation inhibitory [49],
corticosterone secretory [50], hepatoprotective [51], and
nephroprotective [52] activities through their potent
free radical scavenger effects, the antioxidant effects.
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also possessed the most potent antioxidant activity [53].
The present results suggested that BZYQ might effectively
inhibited lipid peroxidation in muscle tissues, and acted
directly or interacted with endogenous antioxidants for
synergistic effects to defend against fatigue caused by PTX
treated. But this effect looked like not obvious in the mice
which did not treated with PTX, the difference of the
mechanism of the oxidative stress caused by tumors and
chemotherapeutic agents need to be further study. And
we need to find out which element of BZYQ act the most
important anti-chemotherapy-related-fatigue effect in the
future studies.
Importantly, the BZYQ + PTX and PTX groups re-
sulted in smaller tumor volume and less tumor weight
compared with the TC group, moreover the mice of the
BZYQ + PTX group had longer median survival times
than the TC group; though there was no significant dif-
ference, the BZYQ + PTX group presented a tendency of
less tumor weight, longer median survival time and
heavier body weight than the PTX group. On the other
hand, the tumor weight of the BZYQ and the TC groups
had no significant difference, but the BZYQ group had a
tendency of decreased tumor weight, longer median sur-
vival times and heavier body weight than the TC group.
Tumor is a kind of wasting disease [54], and gastrointes-
tinal dysfunctional is one of the serious side effects of
PTX [55], in this study, we can assume that BZYQ has
the potential effects on antitumor, improving quality of
life and increasing body weight, which is consistent with
the prior studies [9-17], we need enlarge the sample size
to confirm the hypothesis in the next step.
Conclusions
In conclusion, the present study has demonstrated the po-
tential of BZYQ in alleviating paclitaxel chemotherapy-
related fatigue by reducing the serum level of TNF-α and
modulating the levels of MDA and SOD activity in the
4 T1 murine breast cancer model.
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